Study: CBD May Enhance Treatment Efficiacy in Glioblastoma Multiforme (Brain Tumor)

CBD may “act as an adjunct to enhance treatment efficacy” in glioblastoma multiforme, which is “the most common and aggressive form of primary malignant brain tumor in adults”, according to a study published by the journal Translational Oncology.

“Glioblastoma multiforme (GBM) is the most common and aggressive form of primary malignant brain tumor in adults, with poor prognosis”, states the study’s abstract. “Extracellular vesicles (EVs) are key-mediators for cellular communication through transfer of proteins and genetic material. Cancers, such as GBM, use EV release for drug-efflux, pro-oncogenic signaling, invasion and immunosuppression; thus the modulation of EV release and cargo is of considerable clinical relevance.”

As EV-inhibitors have been shown to increase sensitivity of cancer cells to chemotherapy, “and we recently showed that cannabidiol (CBD) is such an EV-modulator”, researchers “investigated whether CBD affects EV profile in GBM cells in the presence and absence of temozolomide (TMZ).” Compared to controls, “CBD-treated cells released EVs containing lower levels of pro-oncogenic miR21 and increased levels of anti-oncogenic miR126; these effects were greater than with TMZ alone. In addition, prohibitin (PHB), a multifunctional protein with mitochondrial protective properties and chemoresistant functions, was reduced in GBM cells following 1 h CBD treatment.”

Read moreStudy: CBD May Enhance Treatment Efficiacy in Glioblastoma Multiforme (Brain Tumor)

Study: CBD-Rich Cannabis Extracts Present “a Better Therapeutic Profile” Than Pure CBD

CBD-rich extracts which contain at least a small amounts of other cannabinoids “present a better therapeutic profile” than CBD alone, according to a new study published by the journal Frontiers in Neurology.

Cannabis oil (photo: David Downs).

The study, titled Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy, states that the improved benefits of high-CBD cannabis extracts over pure CBD “is likely due to synergistic effects of CBD with other phytocompounds (aka Entourage effect)”.

According to the study’s abstract. “This meta-analysis paper describes the analysis of observational clinical studies on the treatment of refractory epilepsy with cannabidiol (CBD)-based products. Beyond attempting to establish the safety and efficacy of such products, we also investigated if there is enough evidence to assume any difference in efficacy between CBD-rich extracts compared to purified CBD products.”

Read moreStudy: CBD-Rich Cannabis Extracts Present “a Better Therapeutic Profile” Than Pure CBD

Study: CBD May Help Treat, and Cause the Death of, Endometrial Cancer

CBD (cannabidiol) and CBD-rich extracts may provide a potential treatment option for endometrial cancer, according to a new study published by the Journal of Physiology and Biochemistry, and published online by the U.S. National Institute of Health.

Endometrial cancer,

“Among a variety of phytocannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most promising therapeutic compounds”, begins the study’s abstract. “Besides the well-known palliative effects in cancer patients, cannabinoids have been shown to inhibit in vitro growth of tumor cells. Likewise, the major endocannabinoids (eCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), induce tumor cell death.”

The purpose of the present study “was to characterize cannabinoid elements and evaluate the effect of cannabinoids in endometrial cancer cell viability.” Endometrial cancer is a variety of cancer that begins in the lining of the uterus.

Read moreStudy: CBD May Help Treat, and Cause the Death of, Endometrial Cancer

Study: CBD a “Therapeutic Candidate for Stroke Prevention”

Cannabidiol (CBD) may help to prevent strokes, according to a new study published by the U.S. National Institute of Health.

“The endocannabinoid system (ECS) regulates functions throughout human physiology, including neuropsychiatric, cardiovascular, autonomic, metabolic, and inflammatory states”, begins the study’s abstract, which was published in-print by the journal Cannabis and Cannabinoid Research. “The complex cellular interactions regulated by the ECS suggest a potential for vascular disease and stroke prevention by augmenting central nervous and immune cell endocannabinoid signaling.”

Cannabidiol (CBD), a nonpsychoactive constituent of Cannabis, “is an immediate therapeutic candidate both for potentiating endocannabinoid signaling and for acting at multiple pharmacological targets.” According to reseachers, this “speculative synthesis explores the current state of knowledge of the ECS and suggests CBD as a therapeutic candidate for stroke prevention by exerting favorable augmentation of the homeostatic effects of the ECS and, in turn, improving the metabolic syndrome, while simultaneously stalling the development of atherosclerosis.”

Read moreStudy: CBD a “Therapeutic Candidate for Stroke Prevention”

Study: CBD May Treat Psychiatric/Cognitive Symptoms Associated with Neurodegeneration

Cannabidiol (CBD) may be beneficial in the treatment of psychiatric/cognitive symptoms associated with neurodegeneration, according to a new study.

The study, published by the journal Frontiers in Pharmacology, was also published online by the U.S. National Institute of Health.

“Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression”, begins the study’s abstract. “The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes.”

Read moreStudy: CBD May Treat Psychiatric/Cognitive Symptoms Associated with Neurodegeneration

New Study: Cannabidiol (CBD) Exhibits Strong Anti-Seizure Properties

A new study published by the journal Neurochemical Research, and published online by the U.S. National Institute of Health, has confirmed past research that shows cannabidiol to be an anti-seizure agent.

For the study; “The National Institute of Neurological Disorders and Stroke (NINDS) funded Epilepsy Therapy Screening Program (ETSP) investigated CBD in a battery of seizure models using a refocused screening protocol aimed at identifying pharmacotherapies to address the unmet need in pharmacoresistant epilepsy”.

Applying this new screening workflow, CBD was investigated in multiple mouse and rat models of acute seizures. Following intraperitoneal (i.p.) pretreatment, “CBD produced dose-dependent protection in the acute seizure models.” In chronic models, “CBD produced dose-dependent protection in the corneal kindled mouse”.

Read moreNew Study: Cannabidiol (CBD) Exhibits Strong Anti-Seizure Properties

New Study Finds Cannabidiol Inhibits Growth of Highly Aggressive Breast Cancer

A new study cannabudpublished in the journal Molecular Oncology, and published online by the National Institute of Health, has found that the cannabis compound cannabidiol inhibits the growth and metastasis of highly aggressive breast cancer.

“The anti-tumor role and mechanisms of Cannabidiol (CBD), a non-psychotropic cannabinoid compound, are not well studied especially in triple-negative breast cancer (TNBC)”, says the study’s researchers. “In the present study, we analyzed CBD’s anti-tumorigenic activity against highly aggressive breast cancer cell lines including TNBC subtype.”

Read moreNew Study Finds Cannabidiol Inhibits Growth of Highly Aggressive Breast Cancer